Magnesium: An old player revisited in the context of CKD-MBD

• Published in: Clinica chimica acta 2020-02, Vol.501, p.53-59
• Main Authors: Pendón-Ruiz de Mier, M.V., Rodelo-Haad, C., Díaz-Tocados, J.M., Muñoz-Castañeda, J.R., Rodríguez, M.
• Format: Article
• Language: English
• Subjects: Chronic kidney disease-mineral bone disorder; CKD comorbidities; Magnesium
• ISSN: 0009-8981; 1873-3492
• DOI: 10.1016/j.cca.2019.11.037

•Mg supplementation has been associated with a reduction of vascular calcifications in CKD.•Reduced Mg levels are associated with progression of CKD.•In CKD patients, there is a significant association between serum Mg levels and cardiovascular disease. Additional interventional studies should be performed.•Mineral metabolism and bone health might be affected by Mg. Clinical trials are required to determine with precision the effects of Mg supplementation on bone. Chronic kidney disease (CKD) is associated with a wide number of abnormalities in mineral metabolism. Often, these alterations are the leading players in the development of comorbidities associated with CKD, which are risk factors of mortality. In this context, mineral and bone disorder associated with CKD (CKD-MBD) are highlighted, connecting bone, renal, and cardiovascular disorders. Many studies have been led to propose strategies to avoid, reduce, or slow down CKD-MBD progression using different compositions of metallic elements-based P binders such as aluminum, magnesium, or calcium. Magnesium, the aim of this review, has been used by nephrologists to treat CKD-MBD with a variable acceptation due mainly to different results on bone homeostasis. Nowadays, we have new evidence about the efficacy of magnesium supplementation on vascular calcification, renal function, and bone disorders, suggesting potential beneficial effects of Magnesium in the management of CKD-MBD.